News & Events

Archived News

Translational Medicine Research Collaboration announces first round of research project funding

The Translational Medicine
Research Collaboration (TMRC) -
the unique venture bringing
together one of the world’s
biggest pharmaceutical companies
with Scotland’s finest medical
research centres - today announced
the first round of research
projects to be funded through the
new £50 million initiative.

Almost £8 million of funding has
been released to support 28 new
research projects covering a wide
range of therapeutic areas
including cardiovascular and
metabolic disease, the central
nervous system, oncology,
inflammation, and women’s health.

The projects will commence
imminently across Scotland and, as
a result, over 40 new jobs have
already been created in the
universities while a further 50
new jobs are projected for the
Core Laboratory which will be
located in Dundee.

The Collaboration comprises four
of Scotland’s leading universities
(Aberdeen, Dundee, Edinburgh and
Glasgow), Wyeth Pharmaceutical Co,
Scottish Enterprise and NHS
Scotland Grampian, Greater
Glasgow, Lothian and Tayside, and
provides new impetus for Scotland
to lead the world in the
development of personalised
medicine, bringing new treatments
to patients suffering from a range
of serious illnesses.

Professor Andrew Morris, chair of
the TMRC Steering Group, said:

"This first large injection of
medical research funding into
Centres of Excellence across
Scotland is an important milestone
for TMRC. The spirit of
collaboration between the partners
has been fantastic, and we have
already set our sights on
supporting more researchers in
innovative ways in the months
ahead."

Frank Walsh, Executive Vice
President of Wyeth Discovery, said:

"We are very excited about the
quality of the science that will
be conducted as a result of the
first round of TMRC projects.
Through this first round alone
over 160 scientists across
Scotland will be conducting
research as part of this
collaboration, the results of
which could help drive the
development of novel drugs for
devastating diseases such as
cardiovascular disease and cancer."

Further projects to be funded
through TMRC are already in the
pipeline and applications for a
second round of funding are being
invited from the scientific
community in Scotland.


2007